Golub Group LLC Grows Stake in Baxter International Inc (NYSE:BAX)

Share on StockTwits

Golub Group LLC grew its holdings in Baxter International Inc (NYSE:BAX) by 2.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 30,799 shares of the medical instruments supplier’s stock after buying an additional 876 shares during the quarter. Golub Group LLC’s holdings in Baxter International were worth $2,694,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. 1 North Wealth Services LLC purchased a new position in shares of Baxter International in the 3rd quarter valued at approximately $27,000. Personal Wealth Partners purchased a new position in shares of Baxter International in the 2nd quarter valued at approximately $29,000. TRUE Private Wealth Advisors purchased a new position in shares of Baxter International in the 2nd quarter valued at approximately $29,000. Old North State Trust LLC purchased a new position in shares of Baxter International in the 3rd quarter valued at approximately $31,000. Finally, Evolution Wealth Advisors LLC purchased a new position in shares of Baxter International in the 2nd quarter valued at approximately $32,000. Institutional investors and hedge funds own 83.45% of the company’s stock.

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. set a $94.00 target price on Baxter International and gave the company a “buy” rating in a research note on Tuesday, October 8th. Deutsche Bank assumed coverage on Baxter International in a research note on Monday, October 21st. They issued a “buy” rating and a $109.00 target price for the company. Piper Jaffray Companies restated a “buy” rating on shares of Baxter International in a research note on Tuesday, September 10th. Barclays set a $82.00 target price on Baxter International and gave the company a “hold” rating in a research note on Friday, July 26th. Finally, Credit Suisse Group raised their target price on Baxter International from $84.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $90.14.

In other Baxter International news, SVP Andrew Frye sold 3,332 shares of Baxter International stock in a transaction on Monday, October 14th. The stock was sold at an average price of $88.00, for a total value of $293,216.00. Following the completion of the sale, the senior vice president now owns 16,391 shares of the company’s stock, valued at approximately $1,442,408. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Jacqueline Kunzler sold 5,934 shares of Baxter International stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $88.12, for a total value of $522,904.08. Following the completion of the sale, the senior vice president now directly owns 3,089 shares of the company’s stock, valued at approximately $272,202.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,396 shares of company stock valued at $1,528,575. 0.70% of the stock is owned by corporate insiders.

BAX stock traded up $0.51 on Friday, reaching $78.51. 3,017,392 shares of the company traded hands, compared to its average volume of 2,768,937. Baxter International Inc has a one year low of $61.40 and a one year high of $89.93. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10. The company has a market cap of $39.56 billion, a P/E ratio of 25.74, a price-to-earnings-growth ratio of 2.00 and a beta of 0.97. The firm has a fifty day simple moving average of $84.08 and a 200-day simple moving average of $82.11.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Article: Conference Calls

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.